The Medicines Co. Offers Results of Phase 3 Trial of Cangrelor for Treatment of Patients Undergoing PCI

The Medicines Company(NASDAQ: MDCO) today announced results for its pivotal Phase 3clinical trial of cangrelor, which is in development to preventplatelet activation and aggregation that leads to thrombosis in theacute care setting, including in patients undergoing percutaneouscoronary intervention (PCI). Following the recommendation of the trial's Data Safety MonitoringBoard (DSMB) in July 2012 to continue the protocol as planned, theCHAMPION PHOENIX trial completed enrollment in October 2012. After successful data lock, the data analysis revealed that the protocoldefined primary composite efficacy endpoint of death, myocardialinfarction, ischemia driven revascularization and stent thrombosis at48 hours was met. Cangrelor demonstrated statistically significantimprovement as compared to clopidogrel. Safety outcomes were similarto those observed in prior trials. The trial results are planned tobe presented at a major upcoming scientific meeting. Commenting on the trial and its conduct, Dr. Robert A. Harrington,MD, Professor of Medicine and Chairman of Medicine at StanfordUniversity and Co-Principal Investigator said: "The PHOENIX trial wasdesigned with careful consideration of the prior studies to determinewhether cangrelor is associated with improved ischemic outcomescompared with the usual treatment of oral clopidogrel. We aregrateful to the many investigators around the world who enabled rapidenrollment and the collection of high quality data. We are pleasedthat the trial delivered such clear results.""We are looking forward to presenting detailed results to the medicalcommunity as soon as the data are fully analyzed," said Dr. Deepak L.Bhatt, MD, MPH, Chief of Cardiology at VA Boston Healthcare System,Senior Physician at Brigham and Women's Hospital, Professor ofMedicine at Harvard Medical School and Co-Principal Investigator ofthe CHAMPION Trials. Clive Meanwell MD, PhD, Chairman and Chief Executive Officer of TheMedicines Company added that the Company expects to submit data bothfrom the CHAMPION PHOENIX trial and from the BRIDGE trial in the USAand EU for regulatory review in 2013. "We believe that fast actingand rapidly reversible cangrelor may have an important role to playboth in patients undergoing PCI and in patients who need todiscontinue oral P2Y12 inhibitors prior to surgery," he said.